VCG
CYTK icon

Vantage Consulting Group’s Cytokinetics CYTK Stock Holding History

Vantage Consulting Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,248
Closed -$67K – 465
2020
Q4 		$67K Buy
+3,248
New +$59.4K 0.01% 338

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vantage Consulting Group's CYTK Position: Q1 2021 in Review

Vantage Consulting Group sold out of Cytokinetics (CYTK) in Q1 2021, closing a stake of 3,248 shares — an estimated $67K sold.

Vantage Consulting Group first reported a position in CYTK in Q4 2020 and held it in 1 quarter. The position peaked at $67K in Q4 2020. 192 funds tracked by Wall St. Rank hold CYTK as of Q1 2021.

  • Vantage Consulting Group reported no remaining Cytokinetics position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 3,248 Cytokinetics shares in Q1 2021, an estimated $67K.
  • Vantage Consulting Group first reported a position in Cytokinetics in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Cytokinetics position peaked at $67K in Q4 2020.
  • 192 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.